Reducing Cardiovascular Risk in T2DM with SGLT2 Inhibitors and GLP1-Receptor Agonists: Translating Evidence into Patient Outcomes

Reducing Cardiovascular Risk in T2DM with SGLT2 Inhibitors and GLP1-Receptor Agonists: Translating Evidence into Patient Outcomes is organized by Association of Diabetes Care & Education Specialists (ADCES).

Originally presented on: 8/19/2018
Expiration date: 11/26/2020

Intended Audience:
The AADE Webinars are knowledge-based activities designed for individual or groups of diabetes educators, including RNs, RDs, Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, Physician Assistants, MDs, and other health care providers interested in staying up to date on current practices of care for their patients with diabetes and other related conditions.

Accreditation Information:
Registered Nurses:
This educational program will provide 1.0 contact hours of continuing education credit. 

Registered Dietitians:
The American Association of Diabetes Educators, (AM001) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.0 continuing professional education units (CPEUs) for completion of this program. Continuing Professional Education Provider Accreditation does not constitute endorsement by CDR of a provider, program, or materials.

Registered Pharmacists:
The American Association of Diabetes Educators is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 1.0 contact hours (0.10 CEUs) of continuing education credit / 1.0 CE credits.

Overview:
Despite the availability of multiple therapeutic classes, the majority of conventional antidiabetic agents fail to address macrovascular risk factors and subsequent complications associated with type 2 diabetes mellitus (T2DM). As such, cardiovascular disease (CVD) remains the leading cause of death among people living with T2DM. Fortunately, emerging clinical evidence demonstrates that novel antidiabetic agents, such as sodium-glucose co-transport-2 (SGLT-2) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) not only improve glycemic control and microvascular complications but also demonstrate meaningful clinical impacts on CVD risk reduction. 

Ensuring that these advances translate into real-world benefits for people with T2DM relies on the identification of people who are most likely to benefit from novel agents and their appropriate use as part of individualized treatment paradigms, the management of potential treatment-related adverse events, and importantly, the requirement of individuals to be persistent with these therapies as part of multimodal CV risk reduction strategies. 

This symposium reviews the latest data on cardiovascular outcomes related to use of SGLT-2 inhibitors and GLP-1RAs, among other blood sugar lowering agents, the impact of available and emerging data on care and clinical outcomes. Importantly, this activity addresses practical diabetes educator-driven strategies to optimize the appropriate use of novel agents as part of T2DM and CVD self-management.

Learning Objectives
At the end of this presentation, the participant will be able to: 
• Recognize the efficacy, safety, and impact of SGLT-2 inhibitors and GLP-1RAs in reducing micro- and macrovascular disease and nephropathy. 
• Identify individuals living with diabetes who are likely to benefit from pharmacological agents that reduce micro- and macrovascular risk reduction as part of individualized T2DM treatment strategies. 
• Propose techniques to provide specific education to individuals living with diabetes regarding the use of SGLT-2 inhibitors and GLP-1RAs as part of micro- and macrovascular risk reduction strategies.